TriangleAtezolizumab (NCT04981509)
Atezolizumab trial for Hereditary Leiomyomatosis and Renal Cell Carcinoma (NCT04981509). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged 12 or older with advanced HLRCC-associated kidney cancer or sporadic papillary kidney cancer. Prior bevacizumab or PD-1/PD-L1 therapy for advanced disease is excluded; no prior treatment is required.
The idea: combine intravenous bevacizumab and atezolizumab with daily oral erlotinib. Bevacizumab blocks new blood-vessel formation, erlotinib blocks EGFR growth signals, and atezolizumab aims to support immune attack. Researchers assess tumor response and safety in 21-day treatment cycles.
This phase 2 study plans 65 patients. Ramaprasad Srinivasan leads through NCI; six US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.